title: Minocycline and talc slurry pleurodesis for patients with secondary spontaneous pneumothorax.
abstract: METHODS
  Few studies have evaluated the sclerosing efficacy of minocycline, and none have specifically compared its sclerosing efficacy and safety profiles with talc slurry in secondary spontaneous pneumothorax (SSP).
  
  
  METHODS
  A retrospective analysis was conducted in patients with SSP who underwent chemical pleurodesis from January to December 2004 with minocycline or talc slurry in 12 public hospitals of Hong Kong.
  
  
  RESULTS
  There were 121 episodes of minocycline pleurodesis and 64 episodes of talc slurry pleurodesis. Immediate procedural failure were similar in the minocycline and talc slurry groups (21.5% vs. 28.1%, P = 0.31). Presence of interstitial lung disease, ≥ 2 previous episodes of pneumothorax, requiring mechanical ventilation during pleurodesis and persistent air leak before pleurodesis were independently associated with procedural failure. Pain was experienced in respectively 44.6% and 37.5% of the minocycline and the talc slurry groups. Pain was more common in patients receiving high doses of talc (≥ 5 g; P = 0.03). Respiratory distress was found in respectively 1.7% and 1.6% of the minocycline and talc slurry groups.
  
  
  CONCLUSIONS
  Minocycline and talc slurry had comparable sclerosing efficacy in SSP, with immediate success rates of >70%. Pain was the most common adverse effect and respiratory distress was uncommon. Both appeared to be effective and safe for chemical pleurodesis in SSP.
authors.affiliation: Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong SAR, China. ngck6@ha.org.hk
authors.forename: C K
authors.initials: CK
authors.lastname: Ng
authors.forename: F W
authors.initials: FW
authors.lastname: Ko
authors.forename: J W
authors.initials: JW
authors.lastname: Chan
authors.forename: A
authors.initials: A
authors.lastname: Yeung
authors.forename: W K S
authors.initials: WK
authors.lastname: Yee
authors.forename: L K Y
authors.initials: LK
authors.lastname: So
authors.forename: B
authors.initials: B
authors.lastname: Lam
authors.forename: M M L
authors.initials: MM
authors.lastname: Wong
authors.forename: K L
authors.initials: KL
authors.lastname: Choo
authors.forename: A S S
authors.initials: AS
authors.lastname: Ho
authors.forename: P Y
authors.initials: PY
authors.lastname: Tse
authors.forename: S L
authors.initials: SL
authors.lastname: Fung
authors.forename: C K
authors.initials: CK
authors.lastname: Lo
authors.forename: W C
authors.initials: WC
authors.lastname: Yu
mesh_terms: D000368:Aged; D016009:Chi-Square Distribution; D002681:China; D005260:Female; D006779:Hospitals, Public; D006785:Hospitals, University; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage*; D016017:Odds Ratio; D010146:Pain / Q000209:etiology; D018700:Pleurodesis / Q000009:adverse effects / Q000379:methods*; D011030:Pneumothorax / Q000209:etiology / Q000628:therapy*; D012120:Respiration Disorders / Q000209:etiology; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012597:Sclerosing Solutions / Q000008:administration & dosage*; D055502:Secondary Prevention; D013627:Talc / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D012597:Sclerosing Solutions; D013627:Talc; D008911:Minocycline